Clark Estates Inc. NY Has $2,625,000 Position in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP)

Clark Estates Inc. NY maintained its stake in shares of Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) during the second quarter, according to its most recent disclosure with the SEC. The firm owned 250,000 shares of the biopharmaceutical company’s stock at the end of the second quarter. Clark Estates Inc. NY owned approximately 0.54% of Sucampo Pharmaceuticals worth $2,625,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in the stock. Bank of Montreal Can boosted its stake in shares of Sucampo Pharmaceuticals by 22.9% in the first quarter. Bank of Montreal Can now owns 24,775 shares of the biopharmaceutical company’s stock worth $272,000 after buying an additional 4,615 shares during the period. State Street Corp boosted its stake in shares of Sucampo Pharmaceuticals by 32.9% in the fourth quarter. State Street Corp now owns 581,835 shares of the biopharmaceutical company’s stock worth $7,882,000 after buying an additional 143,906 shares during the period. Virginia Retirement Systems ET AL acquired a new stake in shares of Sucampo Pharmaceuticals during the first quarter worth approximately $536,000. Bank of New York Mellon Corp boosted its stake in shares of Sucampo Pharmaceuticals by 107.3% in the first quarter. Bank of New York Mellon Corp now owns 367,691 shares of the biopharmaceutical company’s stock worth $4,044,000 after buying an additional 190,292 shares during the period. Finally, Adams Diversified Equity Fund Inc. boosted its stake in shares of Sucampo Pharmaceuticals by 2.9% in the first quarter. Adams Diversified Equity Fund Inc. now owns 53,400 shares of the biopharmaceutical company’s stock worth $587,000 after buying an additional 1,500 shares during the period. Hedge funds and other institutional investors own 58.20% of the company’s stock.

Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) opened at 10.25 on Friday. The company’s market cap is $474.83 million. Sucampo Pharmaceuticals, Inc. has a 52 week low of $9.30 and a 52 week high of $17.55. The company has a 50-day moving average of $10.71 and a 200-day moving average of $10.68.

Sucampo Pharmaceuticals (NASDAQ:SCMP) last issued its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported $0.28 earnings per share for the quarter, beating analysts’ consensus estimates of $0.22 by $0.06. Sucampo Pharmaceuticals had a positive return on equity of 56.58% and a negative net margin of 61.99%. The company had revenue of $59.90 million for the quarter, compared to the consensus estimate of $56.44 million. During the same quarter last year, the company earned $0.24 earnings per share. The firm’s revenue for the quarter was up 15.3% compared to the same quarter last year. On average, equities analysts expect that Sucampo Pharmaceuticals, Inc. will post $1.02 EPS for the current year.

TRADEMARK VIOLATION WARNING: This news story was first published by Stock Observer and is the sole property of of Stock Observer. If you are reading this news story on another site, it was copied illegally and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this news story can be read at https://www.thestockobserver.com/2017/08/12/clark-estates-inc-ny-has-2625000-position-in-sucampo-pharmaceuticals-inc-nasdaqscmp.html.

SCMP has been the topic of a number of research reports. ValuEngine upgraded shares of Sucampo Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, June 23rd. Zacks Investment Research upgraded shares of Sucampo Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Tuesday, July 4th. Roth Capital set a $30.00 target price on shares of Sucampo Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, August 3rd. Jefferies Group LLC dropped their target price on shares of Sucampo Pharmaceuticals from $13.00 to $11.00 and set a “hold” rating on the stock in a report on Thursday, May 4th. Finally, Maxim Group restated a “buy” rating and set a $23.00 target price (up previously from $21.00) on shares of Sucampo Pharmaceuticals in a report on Tuesday. Three investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $17.63.

In related news, insider Jones W. Bryan acquired 4,700 shares of the company’s stock in a transaction that occurred on Friday, August 4th. The shares were bought at an average price of $10.60 per share, with a total value of $49,820.00. Following the completion of the transaction, the insider now directly owns 4,700 shares in the company, valued at $49,820. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 4.13% of the stock is owned by company insiders.

About Sucampo Pharmaceuticals

Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.

Want to see what other hedge funds are holding SCMP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP).

Institutional Ownership by Quarter for Sucampo Pharmaceuticals (NASDAQ:SCMP)

Receive News & Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply